Clinical TrialsCellectis is on track to initiate a pivotal Phase 2 trial for lasme-cel in relapsed/refractory B-ALL.
Financial PositionManagement anticipates that the cash position is strong, with approximately $246 million in cash, cash equivalents, restricted cash, and fixed-term deposits.
Strategic PartnershipsCellectis is progressing their R&D stage programs in collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies and solid tumors.